程序性死亡因子配体1在肝细胞癌中的表达及意义

杨柳; 朱曦龄; 黎功

doi:10.3969/j.issn.1001-5256.2016.08.047

程序性死亡因子配体1在肝细胞癌中的表达及意义

DOI: 10.3969/j.issn.1001-5256.2016.08.047

安徽医科大学武警总医院临床学院肿瘤二科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2021
- HTML全文浏览量: 19
- PDF下载量: 448
- 被引次数: 0
出版历程
- 收稿日期: 2016-02-22
- 出版日期: 2016-08-20

Expression of programmed death-ligand 1 in hepatocellular carcinoma and its clinical significance

Second Department of Oncology,Clinical College of General Hospital of Armed Police Forces,Anhui Medical University

摘要

摘要: 近年来以阻断PD-1/PD-L1通路为基础的免疫治疗在黑色素瘤、肺癌等恶性肿瘤中取得令人鼓舞的进展,其在肝细胞癌中的研究也在逐渐展开。介绍了PD-1/PD-L1作用机制、肝细胞癌组织中PD-L1的表达情况以及其在肝细胞癌治疗领域的基础及临床研究。认为PD-L1在肿瘤免疫逃逸中发挥重要作用,有望成为判断肝细胞癌预后的独立指标,PD-1/PD-L1通路的发现为肝细胞癌的免疫治疗提供了新的靶点。
- 癌,肝细胞 /
- 程序性死亡因子配体1 /
- 免疫疗法 /
- 综述
Abstract: In recent years,the immunotherapy based on the blocking of programmed death- 1( PD- 1) / programmed death- ligand 1( PD- L1)pathway has achieved encouraging progress in the treatment of malignant tumors such as melanoma and lung cancer. More and more studies have focused on its role in hepatocellular carcinoma( HCC). This article introduces the mechanism of action of PD- 1 / PD- L1,expression of PD- L1 in HCC tissues,and its basic and clinical research in the treatment of HCC,and points out that PD- L1 plays an important role in tumor immune escape and is expected to become an independent index for evaluating the prognosis of HCC. The discovery of PD- 1 / PD- L1 pathway provides a new target for immunotherapy for HCC.
- carcinoma /
- hepatocellular /
- programmed death ligand 1 /
- immunotherapy

HTML全文

参考文献(29)

[1]DONG H,ZHU G,TAMADA K,et al.B7-H1,a third member of the B7 family,co-stimulates T-cell proliferation and interleukin-10 secretion[J].Nat Med,1999,5(12):1365-1369.

[2]CHEN DS,MELLMAN I.Oncology meets immunology:the cancerimmunity cycle[J].Immunity,2013,39(1):1-10.

[3]VESELY MD,SCHREIBER RD.Cancer immunoediting:antigens,mechanisms,and implications to cancer immunotherapy[J].Ann N YAcad Sci,2013,1284(1):1-5.

[4]ZOU W,CHEN L.Inhibitory B7-family molecules in the tumour microenvironment[J].Nat Rev Immunol,2008,8(6):467-477.

[5]DU LL,HE LL,ZHAO YL,et al.Research advances in immunoregulatory effect of PD-1/PD-LI in Chronic hepatitis B-related primary liver cancer[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition,2014,8(6):860-862.(in Chinese)杜林林,何玲玲,赵亚林,等.PD-1/PD-L1在慢性乙型肝炎相关原发性肝癌中免疫调节作用的研究进展[J/CD].中华实验和临床感染病杂志:电子版,2014,8(6):860-862.

[6]ZANG X,ALLISON JP.The B7 family and cancer therapy:costimulation and coinhibition[J].Clin Cancer Res,2007,13(18):5271-5279.

[7]OKAZAKI T,HONJO T.PD-1 and PD-1 ligands:from discovery to clinical application[J].Int Immunol,2007,19(7):813-824.

[8]HOFMEYER KA,JEON H,ZANG X.The PD-1/PD-L1(B7-H1)pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion[J].J Biomed Biotechnol,2011,2011(6):71-81.

[9]FIFE BT,PAUKEN KE,EAGAR TN,et al.Interactions between PD-1 and PD-L1 promote tolerance by blocking theT CR-induced stop signal[J].Nat Immunol,2009,10(11):1185-1192.

[10]PATSOUKIS N,BROWN J,PETKOVA V,et al.Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation[J].Sci Signal,2012,5(230):1755-1762.

[11]AMARNATH S,MANGUS CW,WANG JC,et al.The PDL1-PD1axis converts human TH1 cells into regulatory T cells[J].Sci Transl Med,2011,3(111):111-120.

[12]AFREEN S,DERMIME S.The immunoinhibitory B7-H1 molecule as a potential target in cancer:killing many birds with one stone[J].Hematol Oncol Stem Cell Ther,2014,7(1):1-17.

[13]SHEN MQ,SUN CY,LIU ZJ.Expression and clinical significance of B7-H1 and PD-1 in primary hepatocellular carcinoma tissues[J].World Chin J Dig,2008,16(27):3110-3113.(in Chiese)申民强,孙趁意,刘占举.B7-H1及其受体PD-1分子在原发性肝癌组织中的表达及临床意义[J].世界华人消化杂志,2008,16(27):3110-3113.

[14]GAO Q,WANG XY,QIU SJ,et al.Overexpression of PD-L1significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma[J].Clin Cancer Res,2009,15(3):971-979.

[15]WU K,KRYCZEK I,CHEN L,et al.Kupffer cell suppression of CD8+T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions[J].Cancer Res,2009,69(20):8067-8075.

[16]WANG BJ,BAO JJ,WANG JZ,et al.Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma[J].World J Gastroentero,2011,17(28):3322-3329.

[17]UMEMOTO Y,OKANO S,MATSUMOTO Y,et al.Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy[J].J Gastroenterol,2014,50(1):1-11.

[18]KAN G,DONG W.The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology[J].Eur Rev Med Pharmacol Sci,2015,19:3063-3071.

[19]WU P,WU D,LI L,et al.PD-L1 and survival in solid tumors:a meta-analysis[J].PLoS One,2015,10(6):e0131403.

[20]PARDOLL DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.

[21]WILKE CM,WEI S,WANG L,et al.Dual biological effects of the cytokines interleukin-10 and interferon-γ[J].Cancer Immunol Immun,2011,60(11):1529-1541.

[22]CHEN J,LI G,MENG H,et al.Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas[J].Cancer Immunol Immun,2012,61(1):101-108.

[23]BERTINO G,DEMMA S,ARDIRI A,et al.The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies[J].Biomed Res Int,2015,2015(5):1-12.

[24]WAHL DR,STENMARK MH,TAO Y,et al.Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma[J].J Clin Oncol,2015,34(5):452-459.

[25]COUZIN-FRANKEL J.Breakthrough of the year 2013.Cancer immunotherapy[J].Science,2013,342(6165):1432-1433.

[26]SHI F,SHI M,ZENG Z,et al.PD-1 and PD-L1 upregulation promotes CD8(+)T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients[J].Int J Cancer,2011,128:887-896.

[27]ZHANG MN.Clinical significance of PD-1 in human hepatocellular carcinoma[D].Beijing:Chinese PLA Postgraduate Medical School,2009.(in Chinese)张敏娜.肝细胞癌患者PD-1表达及其临床意义研究[D].北京:中国人民解放军军医进修学院,2009.

[28]XIA Y,CHEN R,YE SL,et al.Inhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration and invasion of hepatocellular carcinoma[J].Clin Exp Metastasis,2011,28(7):661-674.

[29]SAWADA Y,YOSHIKAWA T,SHIMOMURA M,et al.Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes[J].Int J Oncol,2015,46(1):28-36.

施引文献

资源附件(0)

访问统计